SINGLE CYCLE REPLICATING ADENOVIRUS VECTORS

• US 20200002725A1
• Filed: 09/13/2019
• Published: 01/02/2020
• Est. Priority Date: 03/06/2008
• Status: Active Grant

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Barry, Michael A., Weaver, Eric
• Granted Patent: US 10,640,786 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/542 oral/gastrointestinal
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector

Abstract

This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.

Claims

1. A method for inducing an immune response against an antigen in a mammal, wherein said method comprises administering an adenovirus to said mammal under conditions wherein said adenovirus infects a cell of said mammal, wherein said adenovirus comprises an adenovirus polypeptide and lacks at least a portion of a nucleic acid sequence that encodes said adenovirus polypeptide, wherein said adenovirus comprises a nucleic acid sequence encoding said antigen, and wherein expression of said antigen in said cell leads to induction of said immune response.

2. The method of claim 1, wherein said mammal is a human.

3. The method of claim 1, wherein said antigen is a tumor antigen.

4. The method of claim 3, wherein said tumor antigen is NY-ESO, EBV-LMP, or a papilloma virus antigen.

5. The method of claim 1, wherein said cell is an epithelial cell, a tumor cell, a hematopoietic cell, or an antigen presenting cell.

6. The method of claim 1, wherein said adenovirus polypeptide is a fiber protein, a V protein, hexon, penton-base, or pIII.

7. A method for delivering a therapeutic polypeptide to a mammal, wherein said method comprises administering an adenovirus to said mammal under conditions wherein said adenovirus infects a cell of said mammal, wherein said adenovirus comprises an adenovirus polypeptide and lacks at least a portion of a nucleic acid sequence that encodes said adenovirus polypeptide, wherein said adenovirus comprises a nucleic acid sequence encoding said therapeutic polypeptide.

8. The method of claim 7, wherein said mammal is a human.

9. The method of claim 7, wherein said therapeutic polypeptide is a thymidine kinase, a fusogenic glycoprotein, a tumor suppressor p53, a heat shock protein polypeptide.

10. The method of claim 7, wherein said cell is a tumor cell, a hematopoietic cell, a liver cell, or a gastrointestinal cell.

11. The method of claim 7, wherein said adenovirus polypeptide is a fiber protein, a V protein, hexon, penton-base, or pIII.